TY - JOUR
T1 - European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care
T2 - European ADPKD Forum and Multispecialist Roundtable participants
AU - Harris, Tess
AU - Sandford, Richard
AU - De Coninck, Brenda
AU - Devuyst, Olivier
AU - Drenth, Joost P.H.
AU - Ecder, Tevfik
AU - Kent, Alastair
AU - Gansevoort, Ron T.
AU - Górriz, Joś Luis
AU - Ong, Albert C.M.
AU - Pirson, Yves
AU - Torres, Vicente E.
AU - Budde, Klemens
AU - Cĺment, Denis
AU - Derchi, Lorenzo E.
AU - Eleftheroudi, Marianna
AU - Levtchenko, Elena
AU - Peters, Dorien
AU - Van Poppel, Hendrik
AU - Vanholder, Raymond
N1 - Funding Information:
The EAF was initiated by, and is currently solely supported by, Otsuka Pharmaceutical Europe Ltd. The EAF Multispecialist Roundtable was co-sponsored by Otsuka Pharmaceutical Europe Ltd and Ipsen Farmaceutica BV. No participants in the EAF initiative or in the Multispecialist Roundtable received fees in respect of these projects. The EAF Report and this Multispecialist Position Paper contents are the opinions of the authors and do not necessarily represent those of the sponsors. Editorial support in the development of this article was provided by Interel, London, UK, funded by Otsuka and Ipsen.
Funding Information:
T.H. reports non-financial support from Otsuka Pharmaceutical Europe Ltd, during the conduct of the study; non-financial support from Otsuka Pharmaceutical Europe Ltd, grants from Otsuka Pharmaceutical Europe Ltd, and personal fees from Otsuka Pharmaceutical UK Ltd, outside the submitted work. R.S. reports personal fees from Otsuka, outside the submitted work. B. De Coninck reports grants from Otsuka and from Ipsen, outside the submitted work. O.D. reports grants from Otsuka, outside the submitted work. J.P.H.D. has served as consultant for Gilead and Abbvie, and has been member of advisory boards of Gilead, BMS, Janssen and Abbvie. The Radboudumc, on behalf of J.P.H.D., received honoraria or research grants from Novartis, Zambon, Ipsen, Otsuka, Falk, Merck, Janssen, AbbVie, and Norgine. T.G. is a member of the Steering Committees of the TEMPO 3:4 (tol-vaptan), REPRISE (tolvaptan) and DIPAK (lanreotide) studies, and received grants for research provided by Otsuka (manufacturer of tolvaptan) and Ipsen (manufacturer of lanreotide). All fees are paid to his employer. J.L.G. reports personal fees from Otsuka, during the conduct of the study. A.C.M.O. reports personal fees and other from Otsuka, outside the submitted work. Y.P. reports personal fees from Cliniques universitaires St Luc, outside the submitted work. V.T. reports grant, non-financial support and other from Otsuka during the conduct of the study; grants from Otsuka, non-financial support and other from Vertex, grant from Palladio, and personal fees from UptoDate, outside the submitted work. T.E. and A.K. declare no conflict of interest.
Publisher Copyright:
© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterized by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations. Individuals with ADPKD should have access to lifelong, multidisciplinary, specialist and patient-centred care involving: (i) a holistic and comprehensive assessment of the manifestations, complications, prognosis and impact of the disease (in physical, psychological and social terms) on the patient and their family; (ii) access to treatment to relieve symptoms, manage complications, preserve kidney function, lower the risk of cardiovascular disease and maintain quality of life; and (iii) information and support to help patients and their families act as fully informed and active partners in care, i.e. to maintain self-management approaches, deal with the impact of the condition and participate in decision-making regarding healthcare policies, services and research. Building on discussions at an international roundtable of specialists and patient advocates involved in ADPKD care, this article sets out (i) the principles for a patient-centred, holistic approach to the organization and delivery of ADPKD care in practice, with a focus on multispecialist collaboration and shared-decision making, and (ii) the rationale and knowledge base for a route map for ADPKD care intended to help patients navigate the services available to them and to help stakeholders and decision-makers take practical steps to ensure that all patients with ADPKD can access the comprehensive multispecialist care to which they are entitled. Further multispecialty collaboration is encouraged to design and implement these services, and to work with patient organizations to promote awareness building, education and research.
AB - Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterized by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations. Individuals with ADPKD should have access to lifelong, multidisciplinary, specialist and patient-centred care involving: (i) a holistic and comprehensive assessment of the manifestations, complications, prognosis and impact of the disease (in physical, psychological and social terms) on the patient and their family; (ii) access to treatment to relieve symptoms, manage complications, preserve kidney function, lower the risk of cardiovascular disease and maintain quality of life; and (iii) information and support to help patients and their families act as fully informed and active partners in care, i.e. to maintain self-management approaches, deal with the impact of the condition and participate in decision-making regarding healthcare policies, services and research. Building on discussions at an international roundtable of specialists and patient advocates involved in ADPKD care, this article sets out (i) the principles for a patient-centred, holistic approach to the organization and delivery of ADPKD care in practice, with a focus on multispecialist collaboration and shared-decision making, and (ii) the rationale and knowledge base for a route map for ADPKD care intended to help patients navigate the services available to them and to help stakeholders and decision-makers take practical steps to ensure that all patients with ADPKD can access the comprehensive multispecialist care to which they are entitled. Further multispecialty collaboration is encouraged to design and implement these services, and to work with patient organizations to promote awareness building, education and research.
KW - ADPKD
KW - CKD
KW - clinical practice
KW - multispecialist care
KW - polycystic kidney disease
UR - http://www.scopus.com/inward/record.url?scp=85045439099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045439099&partnerID=8YFLogxK
U2 - 10.1093/ndt/gfx327
DO - 10.1093/ndt/gfx327
M3 - Article
C2 - 29309655
AN - SCOPUS:85045439099
SN - 0931-0509
VL - 33
SP - 563
EP - 573
JO - Nephrology Dialysis Transplantation
JF - Nephrology Dialysis Transplantation
IS - 4
ER -